Skip to content
The Nexus
HEALTHJun 23 · 11:30 UTCSTAT NEWSAllison DeAngelis

STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

Serapha Bio, a gene-editing startup, secured $230 million in funding and a Chinese licensing deal through a reverse merger with Boundless Bio. The company aims to develop a one-time treatment for Alpha-1 Antitrypsin Deficiency (AATD), a liver and lung disease, with founding investors RA Capital and RTW Investments.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Serapha BioorganizationRA CapitalorganizationRTW InvestmentsorganizationBoundless BioorganizationAlpha-1 Antitrypsin DeficiencytopicChinese drug companyorganization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting